Fulcrum Therapeutics (FULC) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

FULC Fulcrum Therapeutics

Watchlist

3.850
-0.100-2.53%

Close Nov 29 13:00 ET

3.990
+0.140+3.64%

Post 17:01 ET

207.66MMarket Cap-13275P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
Yahoo FinanceNov 28 12:00 ET
Fulcrum Therapeutics to Participate in Upcoming December Conferences
GlobeNewswireNov 26 16:05 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
TipRanksNov 19 02:20 ET · Ratings
Fulcrum Therapeutics Slides As Insider Purchases Lose Another US$362k
Simply Wall StNov 16 08:18 ET
Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $14
Moomoo NewsNov 14 08:35 ET · Ratings
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Moomoo NewsNov 14 07:31 ET · Ratings

Comments

Bigmoney Dreamer

Sep 26 19:48

$Fulcrum Therapeutics (FULC.US)$ 👀lot of meat on forcast but pattern is behaving like walking drunk man….

Jaguar8

Sep 12 07:11

NEWS

$Fulcrum Therapeutics (FULC.US)$
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...

Trytosaveabit

Jul 31 12:53

Up is the way!

$Fulcrum Therapeutics (FULC.US)$ Low volume indeed! But low or high volume, all that matters is that it’s moving up nicely

Trytosaveabit

Jul 31 06:11

Talk about a under estimated or a killer unexpected operating income! Hehehe!

$Fulcrum Therapeutics (FULC.US)$ Fulcrum Therapeutics Q2 Operating Income USD 52.492 Million Vs. IBES Estimate USD 361.4 Thousand! Hope the rest of the earnings looks like this? hehehe

Trytosaveabit

May 23 08:23

Note the timeline

$Fulcrum Therapeutics (FULC.US)$ Its lead candidate, Losmapimod, is a selective p38α/β mitogen-activated protein kinase inhibitor. It is a potentially transformative treatment for FSHD, a rare and debilitating disease for which no approved treatments exist. The FDA has since granted Losmapimod Fast Track designation and Orphan Drug Designation for treating this condition. It is undergoing a Phase 3 study, and Fulcrum expects to report topline data in the fourth quarter of 2024.